Amgen and Xencor to Co-Develop Xencor's Antibody for Autoimmune Diseases
Amgen (Thousand Oaks, CA) and Xencor, Inc. (Monrovia, CA) will collaborate to develop XmAb5871, an Fc-engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases.
Amgen (Thousand Oaks, CA) and Xencor, Inc. (Monrovia, CA) will collaborate to develop XmAb5871, an Fc-engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in late-stage preclinical development for the treatment of autoimmune diseases.
Xencor's CD32b technology is an immunomodulatory platform consisting of engineered Fc domains with selective high affinity binding to FcyRIIb (CD32b), a receptor with dominant inhibitory activity on B cells and other immune cells. The CD32b pathway has never been therapeutically exploited and applied to high-affinity antibodies targeting immune cells.
Under the terms of the agreement, Amgen has the option to an exclusive worldwide license following the completion of a predefined Phase 2 study. Xencor will lead all clinical development until that time. Xencor will receive an upfront payment, and early development milestone payments. If Amgen does exercise its option, Amgen will assume responsibility for future development. Xencor will receive an option-exercise fee which, combined with the upfront and early development milestones, will total $75 million, and Xencor could receive up to an additional $425 million in clinical, regulatory, and commercialization milestone payments.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
